IPOs 2021 (US BIOTECH)

Last Update: Oct 8, 2021

Company Targets Indications Lead Phase
AEON BiopharmaInjectable botulinum toxinCervical dystonia, migraine preventionII
Cognition TherapeuticsTMEM97 (σ-2 antagonist)Alzheimer's, Dementia, dry AMD, synucleinopathiesII
Pyrix OncologyAnti EDB, Anti-DLK1, Anti-CD123 ADCsSolid/hematological malignanciesPreclin
Theseus Pharmaceuticalspan-variant TKIs (KIT, EGFR)GIST, NSCLC (single-, double- triple-mutant EGFR)IND
ExscientiaAI/data analytics, 5-HT1AOCDI
DICE TherapeuticsIL-17, integrin inhibitors (a4b7, avbx)Psoriasis, IL-17 mediated chronic immunological disorders, IBD, fibrosis, oncologyIND
Tyra BiosciencesFGFR3 (V555) FGFR2, RET, FGFR4Oncology, bladder, bile duct, solid tumors, achondroplasia, NSCLC, thyroid, liverPreclin
Pasithea TherapeuticsIV KetaminePsychiatric, neurological disorders (MDD, TRD, PTSD)R&D
Pharmacyte BiotechEncapsulated genetically engineered live cells implantsPancreatic, abdominal cancers, type 1/2 diabetesII
Dermata TherapeuticsSpongilla lacustris-derived compounds Acne, Psoriasis, Rosacea, Hyperhidrosis, AestheticsII
RenovoRxTargeted delivery of chemotherapyPancreatic, HCCAIII
Tango TherapeuticsPRMT5 MTA-cooperative inhibitor, USP1 inhibitorMTAP-deleted cancers, BRCA-1 mutant cancersPreclin
Eliem Therapeutics PEA prodrug, GABAA PAM positive allosteric modulator, Kv7Diabetic nephropathic pain, lumbosacral pain, major depressive disorder, pain, epilepsy,IIa
Adagio TherapeuticsAntibodiesCOVID, InfluenzaII/III
Omega TherapeuticsHNF4A, CXCL1-8, MYC, SFRP1Liver regeneration, COVID, IPF, HCC, NSCLC, SCLC, alopeciaPreclin
Immuneering Corp. Dual MEK, KRAS4B, PI3K-alphaKRAS cancers, oncology, Alzheimer'sI
Tenaya Therapeutics, Inc.AAV, HDAC6i MYBPC3, PKP2, DWORFgHCM, gARVC, HFrEF, HFpEF heart failure, gDCM cardiomyopathyPreclin
Icosavax, Inc.RSV, hMPV bivalent VLP vaccine candidatesRSV, COVIDI
Rallybio Corp.Polyclonal HPA-1a, C5 inhibitor affibody-ABD fusion, pegylated affibody C5, ENPP1Prevention of FNAIT, PNH, gMG, HPPI+
Nuvalent, Inc.Brain-penetrant ROS1-selective inhibitorROS1 NSCLC, ALK NSCLC, HER2 NSCLCIND
Context TherapeuticsExtended release onapristone, Anti-CD3xClaudin 6 (CLDN6)Breast cancer, ovarian, endometrialII
Candel TherapeuticsOncolytic viruses - adenovirus, HSVPC, Glioma, NSCLC, pancreaticIII
Elicio Therapeutics, Inc.mKRAS, TLR9, CD19, ALK, COVPDAC, CRC, NSCLC, hematological, COVIDI
Caribou BiosciencesCAR T, iPSC derived CAR-NKAllogeneic anti-CD19 CAR T, anti-BCMA CART, CAR-iNKI
AbSci Corp.AI-
HCW Biologics Inc.Bifunctional fusion protein complex, TGFB, SASPPancreatic, solid tumors, pulmonary fibrosis, alopcia areataIND
Erasca, Inc.ERK, SHP2, EGFR, KRAS G12C, RAS-GTP, KRAS G12D, ULK, RAS/MAPK, EGFR D2/D3RAS/MAPK altered solid tumors, EGFRm altered NSCLC, FLT3m, GBMII
TScan TherapeuticsCAR T TCRs HA-1 and HA-2 specific AML, MDS, ALL, HNSCC, cervical, anal, NSCLC, melanomaPreclin
Imago BioSciences, Inc.LSD1 inhibitorThrombocytopenia, myelofibrosis, polycythemia vera, hemoglobinopathies, solid tumorsII
Unicycive Therapeutics Prodrug of nicorandil , lanthanum-based phosphate binding agentAKI
Transcode Therapeutics, Inc.RNA therapeutics, miR-10bOncologyIND
Acumen Pharmaceuticals, Inc.Anti-amyloid-beta oligomer (AβO) antibodyAD/Alzheimer'sI
Aerovate Therapeutics, Inc.Inhaled imatinibPAH
Elevation Oncology, Inc.Anti-HER3NRG1 fusion tumorsII+
Graphite Bio, Inc.Gene editing HSC, B globin, IL2RG, CCR5SCD, XSCID cure, Gaucher
GH Research plc5-MeO DMT psychedelicTreatment resistant depression TRD
Acurx Pharmaceuticals, LLCAntibioticsBacteria
Monte Rosa TherapeuticsGSPT1, CDK2, NEK7, VAV1, BCL11A PROTEIN DEGRADATIONMYC cancers, ovarian, uterine, BC, inflammatory diseasesPre-IND
Cyteir Therapeutics Synthetic lethality, RAD51 inhibitor Solid tumors, hematologic malignancies I/II
Ambrx BiopharmaAnti-HER2 ADC, Anti-PSMA ADC, anti-CD70 ADC, PEG-IL-2, Anti-CD3 folate bis, TLR agonist ADC, Gastric/GEJ cancer, solid tumors, mCRPC, NSCLC, ovarian, RCC, NHL, AMLIII
ATAI Life Sciences B.V.PsychedelicsPsychiatric
Century Therapeutics, Inc. Allogeneic iPSC-derived NK and T cell therapy, CD19, CD133 x EGFR, CD19 x CD79bOncologyPreclin
Verve Therapeutics PCSK9, ANGPTL3Heterozygous familial hypercholesteremia, familial HCSIND
Lyell Immunopharma, Inc. Epigenetic reprogramming CAR t cellsROR1+ NSCLC, NY-ESO-1
Molecular Partners AGFAP x 4-1BB, FAPxCD40, CD3xCD33xCD70xCD123, T cell engagersOncology, COVID, nAMD, DME I
Alzamend Neuro Lithium, mutant peptide vaccine for ADDementia related to AD
Janux Therapeutics, Inc. PSMA x CD3, EGFR x CD3, TROP2 x CD3, PD-L1 x CD28 bispecificsmCRPC, CRC, TNBC, UC, NSCLC, Solid tumorsIND
Centessa Pharmaceuticals plc Vasopressin V2R, Protein C, Anti-EGFR, A1AT folding corrector, Anti-LIGHT, anti-BDCA2, CD47 lockbody, OX2R agonist, Dual STAT3/5 degrader, EGFR-ex20, EGFR-C797SAutosomal dominant polycystic kidney disease, hemophilia A, B, cutaneous squamous cell carcinoma, alpha-1 antitrypsin deficiency, PAH, IPF, systemic sclerosis, SLE, solid tumors, narcolepsy, AML, NSCLCIII
Day One Biopharmaceuticals Holding Co pan-RAF inhibitor, MEK1/2 inhibitorrelapsed pLGG, RAF-altered solid tumors, MAPK-altered solid tumorsII
Vera Therapeutics, Inc. Anti-BLyS x APRIL (recombinant TACI) (licensed from Merck/atacicept)IgA nephropathyIIb
Anebulo Pharmaceuticals, Inc. CB1 antagonistCannibinoid intoxication
Talaris Therapeutics Autologous cells reprogrammedSolid organ transplantation, severe autoimmune disease
Gyroscope TherapeuticsGene therapy, complementDry AMD, GA II
Valneva SE VaccinesLyme, COVID, ZIKA, C Dificil
Vaccitech plc HBV, MERSVaccines, oncology
Werewolf Therapeutics, Inc. IL-2 conditionally activated, IL-12, IFNaTumorsIND
Rain Therapeutics Inc. MDM2 inhibitorLipsarcoma, intimal sarcoma, HRD+ tumorsIII
Recursion Pharmaceuticals AI DATA ANALYTICS, MEK1/2, PKC and GSK3B, HDAC, superoxide scavenger, Familial adenomatous polyposis (FAP), GM2 gangliosidosis, neurofibromatosis type 2, cerebral cavernous malformation, Batten, Charcot-Marie-Tooth, STK11-mutant NSCLCI+
Biomea Fusion Menin inhibitor, precision oncologyMenin-dependent cancersIND
Reneo Pharmaceuticals PPAR agonistPrimary mitochondrial myopathies, long-chain fatty acid disorders, glyocgen storage disease type VII
VectivBio Holding AG Apraglutide (GLP-2 analog full agonist)Short bowel syndrome, aGVHDIII
Achilles TherapeuticsPersonalised CAR TNSCLC, Melanoma, HNSCC, RCC
Design TherapeuticsGeneTAC DNA binding Friedreich ataxia FA, Myotonic dystrophy type IPreclin
Edgewise TherapeuticsFast skeletal muscle myosin inhibitorDMD, LGMD, CardiacI
Ikena OncologyTEAD, ERK5, AHR, Kynurenine, EP4,Hippo-mutated cancers, KRAS mutant, solid tumors, biomarker enriched MSS CRCI
IN8BioAutologous Gamma-delta T cells CARSolid tumors, GBM
Lava TherapeuticsGamma-delta T cell engagersr/r CLL, MM, AML, mCRPC, solid tumorsI
Finch Therapeutics GroupProbioticsRecurrent C. dificile, UC, Crohn's, Autism, Chronic HBVII+
Instil BioTIL Manufacturing Melanoma, NSCLC, HNSCC, Cervical, CSCC, GYNII
Gain TherapeuticsGLB1 gene GBA1 gene IDUA gene GALC geneGM1 gangliosidosis, Gaucher, Parkinson's, MPS type I, KrabbeLead Op
Terns PharmaceuticalsFXR agonist, VAP-1 inhibior, THR-B agonist, GLP-1R agonistNASHIia
Angion HGF mimetic, TKI, ROCK2 inhibitor, CYP11B2 inhibitorAcute kidney injury (transplant), cardiac surgery-acute kidney injury, ARDS, acute CNS-related injury, FibrosisIII
NanobiotixRadioenhancer nanomedicineOncology
Bolt BiotherapeuticsTLR7/8 agonist-trastuzumab conjugate, Anti-HER2, Anti-CEA, Anti-PD-L1, Anti-TAMHER2+ BC, HER2+ GC, HER2 low BC, NSCLC, CRC, Pancreatic, checkpoint-inhibitor refractory tumors, KRAS/TP53 mutant tumorsI/II
Sensei BiotherapeuticsImmunophage ASPH, HPV-specific E6/E7, Phage, Anti-VISTAASPH+ 1L HNSCC +pembrolizumab, neoadjuvant HNSCC + durvulumab, Merkel cell carcinomaII
Immunocore HoldingsRecombinant TCRs - gp100 antigen, MAGE-A4 antigen, PRAME antigen, NY-ESO antigen, HBV Env, HIV gag Uveal melanoma, NSCLC, gastric, HNSCC, ovarian, synovial sarcoma, breast, endometrial, ovarian, SCLC, HBV, HIVBLA
Longboard Pharmaceuticals5-HT2c agonist, CB2 agonist, S1p receptorEpileptic encephalopathies (Dravet, Lennox-Gastaut), ALS, NeuroinflammationI
Prometheus BiosciencesAnti-TL1A, Anti-TNF super family, GPCR modulatorUC, CD, IBDI
Company Targets Indications
AEON BiopharmaInjectable botulinum toxinCervical dystonia, migraine prevention
Cognition TherapeuticsTMEM97 (σ-2 antagonist)Alzheimer's, Dementia, dry AMD, synucleinopathies
Pyrix OncologyAnti EDB, Anti-DLK1, Anti-CD123 ADCsSolid/hematological malignancies
Theseus Pharmaceuticalspan-variant TKIs (KIT, EGFR)GIST, NSCLC (single-, double- triple-mutant EGFR)
ExscientiaAI/data analytics, 5-HT1AOCD
DICE TherapeuticsIL-17, integrin inhibitors (a4b7, avbx)Psoriasis, IL-17 mediated chronic immunological disorders, IBD, fibrosis, oncology
Tyra BiosciencesFGFR3 (V555) FGFR2, RET, FGFR4Oncology, bladder, bile duct, solid tumors, achondroplasia, NSCLC, thyroid, liver
Pasithea TherapeuticsIV KetaminePsychiatric, neurological disorders (MDD, TRD, PTSD)
Pharmacyte BiotechEncapsulated genetically engineered live cells implantsPancreatic, abdominal cancers, type 1/2 diabetes
Dermata TherapeuticsSpongilla lacustris-derived compounds Acne, Psoriasis, Rosacea, Hyperhidrosis, Aesthetics
RenovoRxTargeted delivery of chemotherapyPancreatic, HCCA
Tango TherapeuticsPRMT5 MTA-cooperative inhibitor, USP1 inhibitorMTAP-deleted cancers, BRCA-1 mutant cancers
Eliem Therapeutics PEA prodrug, GABAA PAM positive allosteric modulator, Kv7Diabetic nephropathic pain, lumbosacral pain, major depressive disorder, pain, epilepsy,
Adagio Therapeutics AntibodiesCOVID, Influenza
Omega Therapeutics HNF4A, CXCL1-8, MYC, SFRP1Liver regeneration, COVID, IPF, HCC, NSCLC, SCLC, alopecia
Immuneering Corp. Dual MEK, KRAS4B, PI3K-alphaKRAS cancers, oncology, Alzheimer's
Tenaya Therapeutics, Inc. AAV, HDAC6i MYBPC3, PKP2, DWORFgHCM, gARVC, HFrEF, HFpEF heart failure, gDCM cardiomyopathy
Icosavax, Inc. RSV, hMPV bivalent VLP vaccine candidatesRSV, COVID
Rallybio Corp. Polyclonal HPA-1a, C5 inhibitor affibody-ABD fusion, pegylated affibody C5, ENPP1Prevention of FNAIT, PNH, gMG, HPP
Nuvalent, Inc. Brain-penetrant ROS1-selective inhibitorROS1 NSCLC, ALK NSCLC, HER2 NSCLC
Context Therapeutics Extended release onapristone, Anti-CD3xClaudin 6 (CLDN6)Breast cancer, ovarian, endometrial
Candel Therapeutics Oncolytic viruses - adenovirus, HSVPC, Glioma, NSCLC, pancreatic
Elicio Therapeutics, Inc. mKRAS, TLR9, CD19, ALK, COVPDAC, CRC, NSCLC, hematological, COVID
Caribou Biosciences CAR T, iPSC derived CAR-NKAllogeneic anti-CD19 CAR T, anti-BCMA CART, CAR-iNK
AbSci Corp. AI-
HCW Biologics Inc. Bifunctional fusion protein complex, TGFB, SASPPancreatic, solid tumors, pulmonary fibrosis, alopcia areata
Erasca, Inc. ERK, SHP2, EGFR, KRAS G12C, RAS-GTP, KRAS G12D, ULK, RAS/MAPK, EGFR D2/D3RAS/MAPK altered solid tumors, EGFRm altered NSCLC, FLT3m, GBM
TScan TherapeuticsCAR T TCRs HA-1 and HA-2 specific AML, MDS, ALL, HNSCC, cervical, anal, NSCLC, melanoma
Imago BioSciences, Inc.LSD1 inhibitorThrombocytopenia, myelofibrosis, polycythemia vera, hemoglobinopathies, solid tumors
Unicycive Therapeutics Prodrug of nicorandil , lanthanum-based phosphate binding agentAKI
Transcode Therapeutics, Inc. RNA therapeutics, miR-10bOncology
Acumen Pharmaceuticals, Inc. Anti-amyloid-beta oligomer (AβO) antibodyAD/Alzheimer's
Aerovate Therapeutics, Inc. Inhaled imatinibPAH
Elevation Oncology, Inc. Anti-HER3NRG1 fusion tumors
Graphite Bio, Inc. Gene editing HSC, B globin, IL2RG, CCR5SCD, XSCID cure, Gaucher
GH Research plc 5-MeO DMT psychedelicTreatment resistant depression TRD
Acurx Pharmaceuticals, LLCAntibioticsBacteria
Monte Rosa TherapeuticsGSPT1, CDK2, NEK7, VAV1, BCL11A PROTEIN DEGRADATIONMYC cancers, ovarian, uterine, BC, inflammatory diseases
Cyteir Therapeutics Synthetic lethality, RAD51 inhibitor Solid tumors, hematologic malignancies
Ambrx Biopharma Anti-HER2 ADC, Anti-PSMA ADC, anti-CD70 ADC, PEG-IL-2, Anti-CD3 folate bis, TLR agonist ADC, Gastric/GEJ cancer, solid tumors, mCRPC, NSCLC, ovarian, RCC, NHL, AML
ATAI Life Sciences B.V.PsychedelicsPsychiatric
Century Therapeutics, Inc. Allogeneic iPSC-derived NK and T cell therapy, CD19, CD133 x EGFR, CD19 x CD79bOncology
Verve Therapeutics PCSK9, ANGPTL3Heterozygous familial hypercholesteremia, familial HCS
Lyell Immunopharma, Inc. Epigenetic reprogramming CAR t cellsROR1+ NSCLC, NY-ESO-1
Molecular Partners AGFAP x 4-1BB, FAPxCD40, CD3xCD33xCD70xCD123, T cell engagersOncology, COVID, nAMD, DME
Alzamend Neuro Lithium, mutant peptide vaccine for ADDementia related to AD
Janux Therapeutics, Inc. PSMA x CD3, EGFR x CD3, TROP2 x CD3, PD-L1 x CD28 bispecificsmCRPC, CRC, TNBC, UC, NSCLC, Solid tumors
Centessa Pharmaceuticals plc Vasopressin V2R, Protein C, Anti-EGFR, A1AT folding corrector, Anti-LIGHT, anti-BDCA2, CD47 lockbody, OX2R agonist, Dual STAT3/5 degrader, EGFR-ex20, EGFR-C797SAutosomal dominant polycystic kidney disease, hemophilia A, B, cutaneous squamous cell carcinoma, alpha-1 antitrypsin deficiency, PAH, IPF, systemic sclerosis, SLE, solid tumors, narcolepsy, AML, NSCLC
Day One Biopharmaceuticals Holding Co pan-RAF inhibitor, MEK1/2 inhibitorrelapsed pLGG, RAF-altered solid tumors, MAPK-altered solid tumors
Vera Therapeutics, Inc. Anti-BLyS x APRIL (recombinant TACI) (licensed from Merck/atacicept)IgA nephropathy
Anebulo Pharmaceuticals, Inc. CB1 antagonistCannibinoid intoxication
Talaris Therapeutics Autologous cells reprogrammedSolid organ transplantation, severe autoimmune disease
Gyroscope TherapeuticsGene therapy, complementDry AMD, GA
Valneva SE VaccinesLyme, COVID, ZIKA, C Dificil
Vaccitech plc HBV, MERSVaccines, oncology
Werewolf Therapeutics, Inc. IL-2 conditionally activated, IL-12, IFNaTumors
Rain Therapeutics Inc. MDM2 inhibitorLipsarcoma, intimal sarcoma, HRD+ tumors
Recursion Pharmaceuticals AI DATA ANALYTICS, MEK1/2, PKC and GSK3B, HDAC, superoxide scavenger, Familial adenomatous polyposis (FAP), GM2 gangliosidosis, neurofibromatosis type 2, cerebral cavernous malformation, Batten, Charcot-Marie-Tooth, STK11-mutant NSCLC
Biomea Fusion Menin inhibitor, precision oncologyMenin-dependent cancers
Reneo Pharmaceuticals PPAR agonistPrimary mitochondrial myopathies, long-chain fatty acid disorders, glyocgen storage disease type V
VectivBio Holding AG Apraglutide (GLP-2 analog full agonist)Short bowel syndrome, aGVHD
Achilles TherapeuticsPersonalised CAR TNSCLC, Melanoma, HNSCC, RCC
Design TherapeuticsGeneTAC DNA binding Friedreich ataxia FA, Myotonic dystrophy type I
Edgewise TherapeuticsFast skeletal muscle myosin inhibitorDMD, LGMD, Cardiac
Ikena OncologyTEAD, ERK5, AHR, Kynurenine, EP4,Hippo-mutated cancers, KRAS mutant, solid tumors, biomarker enriched MSS CRC
IN8BioAutologous Gamma-delta T cells CARSolid tumors, GBM
Lava TherapeuticsGamma-delta T cell engagersr/r CLL, MM, AML, mCRPC, solid tumors
Finch Therapeutics GroupProbioticsRecurrent C. dificile, UC, Crohn's, Autism, Chronic HBV
Instil BioTIL Manufacturing Melanoma, NSCLC, HNSCC, Cervical, CSCC, GYN
Gain TherapeuticsGLB1 gene GBA1 gene IDUA gene GALC geneGM1 gangliosidosis, Gaucher, Parkinson's, MPS type I, Krabbe
Terns PharmaceuticalsFXR agonist, VAP-1 inhibior, THR-B agonist, GLP-1R agonistNASH
Angion HGF mimetic, TKI, ROCK2 inhibitor, CYP11B2 inhibitorAcute kidney injury (transplant), cardiac surgery-acute kidney injury, ARDS, acute CNS-related injury, Fibrosis
NanobiotixRadioenhancer nanomedicineOncology
Bolt BiotherapeuticsTLR7/8 agonist-trastuzumab conjugate, Anti-HER2, Anti-CEA, Anti-PD-L1, Anti-TAMHER2+ BC, HER2+ GC, HER2 low BC, NSCLC, CRC, Pancreatic, checkpoint-inhibitor refractory tumors, KRAS/TP53 mutant tumors
Sensei BiotherapeuticsImmunophage ASPH, HPV-specific E6/E7, Phage, Anti-VISTAASPH+ 1L HNSCC +pembrolizumab, neoadjuvant HNSCC + durvulumab, Merkel cell carcinoma
Immunocore HoldingsRecombinant TCRs - gp100 antigen, MAGE-A4 antigen, PRAME antigen, NY-ESO antigen, HBV Env, HIV gag Uveal melanoma, NSCLC, gastric, HNSCC, ovarian, synovial sarcoma, breast, endometrial, ovarian, SCLC, HBV, HIV
Longboard Pharmaceuticals5-HT2c agonist, CB2 agonist, S1p receptorEpileptic encephalopathies (Dravet, Lennox-Gastaut), ALS, Neuroinflammation
Prometheus BiosciencesAnti-TL1A, Anti-TNF super family, GPCR modulatorUC, CD, IBD

Have feedback? Tweet or DM me @blackseedbio on Twitter, or contact me here.

If you want to get notified when updates are available, please consider subscribing.

SUBSCRIBE